TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04564157
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Study: NCT04564157
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains.~Route of administration: Intravenous infusion.~Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 4 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions.~Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
Study: NCT04915365
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
Study: NCT06331468
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of two IV infusions of cisplatin will be administered on Day 1 and again on Day 8 +/- 1 day. Cisplatin starting dose is 40 mg/m2. Dose reduction is allowed (30 mg/m2) as needed for management of toxicities.
Study: NCT06008808
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib is provided by Incyte Corporation.
Study: NCT04883645
Drug: Imiquimod 5% Cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.
Study: NCT05322590
Drug: BXQ-350
Normalized name: BXQ-350
DrugBank: Saposin C (DB17380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
Study: NCT05748171
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
Study: NCT05748171
Drug: ALLR3
Normalized name: Alogliptin and Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase \[or erwinia-asparaginase in the event of an allergic reaction to PEG-asparaginase\]) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
Study: NCT03176498
Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
Study: NCT04940052
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib will be administered orally twice daily
Study: NCT04940052
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib will be administered orally once daily
Study: NCT04940052
Drug: Trametinib placebo
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib will be administered orally once daily
Study: NCT04940052
Drug: Dabrafenib placebo
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib placebo will be administered orally twice daily
Study: NCT06005662
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
Study: NCT05930782
Drug: Piperaquine Tetraphosphate uncoated tablets
Normalized name: Piperazine
DrugBank: Piperaquine (DB13941)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Piperaquine tetraphosphate hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
Study: NCT05930782
Drug: Piperaquine Tetraphosphate dispersible granules
Normalized name: Disperse Blue 106
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Piperaquine tetraphosphate dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
Study: NCT06194214
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally.
Study: NCT06194214
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered Orally.
Study: NCT05534165
Drug: Tecovirimat
Normalized name: Tecovirimat
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg po BID
Study: NCT04675333
Drug: evorpacept
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Q3W
Study: NCT04675333
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Q3W
Study: NCT04675333
Drug: Cisplatin/Carboplatin; 5FU
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Q3W
Study: NCT05929079
Drug: Retatrutide
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06396039
Drug: BMS-986374
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days.
Study: NCT05338970
Drug: Patritumab Deruxtecan
Normalized name: patritumab deruxtecan
DrugBank: Patritumab (DB12090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
Study: NCT05338970
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration time curve of 5 \[AUC5\] by using the Calvert formula) q3W
Study: NCT00367822
Drug: Lisuride
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00367822
Drug: Ropinirole
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06789367
Drug: perineural Dexamethasone 4mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
Study: NCT06789367
Drug: intravenous Dexamethsone 4mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
Study: NCT05517265
Drug: Calquence
Normalized name: Calquence
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
Study: NCT05517265
Drug: Calquence
Normalized name: Calquence
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acalabrutinib according to Calquence® SmPC.
Study: NCT06789042
Drug: 0.9%NaCl
Normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
Study: NCT06789042
Drug: Dexamethasone 4mg
Normalized name: DEXAMETHASONE 4MG TAB
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20ml 0.2% Ropivacaine + 4mg Dexamethasone
Study: NCT06384352
Drug: YL211
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with YL211 intravenous (IV) infusion.
Study: NCT04855760
Drug: REL-1017
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 tablet
Study: NCT06099769
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mouth once daily (160 mg/day)
Study: NCT06099769
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mouth once daily 300-mg tablet
Study: NCT06099769
Drug: TPC
Normalized name: TPCA-1
DrugBank: TPCA-1 (DB17058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle
Study: NCT05769478
Drug: Amifampridine
Normalized name: Amifampridine
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a single dose of amifampridine (20mg) will be orally administered
Study: NCT05032196
Drug: WVE-003
Normalized name: WVE-003
DrugBank: WVE-003 (DB17870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WVE-003 is a stereopure antisense oligonucleotide (ASO)
Study: NCT06400485
Drug: AMT-676
Normalized name: Amtagvi
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
Study: NCT04593784
Drug: Ciraparantag
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag: 180 mg, intravenous
Study: NCT04637594
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04637594
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04637594
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04637594
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04637594
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06137027
Drug: Cannabidiol Oil
Normalized name: CANNABIDIOL OIL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
Study: NCT05229900
Drug: SGN-ALPV
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given into the vein (IV; intravenously)
Study: NCT00530478
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06286189
Drug: Trazodone Hydrochloride
Normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone 100 mg 30 min before sleep
Study: NCT06329830
Drug: 177Lu-PSMA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.4 GBq (200 mCi) via IV infusion once every 6 weeks for 6 cycles
Study: NCT06329830
Drug: Niraparib abiraterone acetate
Normalized name: abiraterone / niraparib
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual action drug tablet that is taken orally by the participant once per day in one of the following dose combinations depending on the cohort assignment and number of dose-limiting toxicities: 200 mg/1000 mg, 150 mg/1000 mg, 100 mg/1000 mg, 50 mg/500 mg
Study: NCT06329830
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg orally twice per day
Study: NCT05168202
Drug: CC-95251
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05168202
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05168202
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06531109
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As provided in the real world practice.
Study: NCT05108870
Drug: HB-201
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A anti-cancer vaccine that treats HPV-related cancers.
Study: NCT05108870
Drug: HB-202
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A anti-cancer vaccine that treats HPV-related cancers.
Study: NCT05108870
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy drug.
Study: NCT05108870
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy drug.
Study: NCT05748834
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.
Study: NCT05748834
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).
Study: NCT04866654
Drug: Nivolumab 10 MG/ML
Normalized name: nivolumab 10 MG/ML
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab, 100 mg, 10 mg/ml
Study: NCT05014087
Drug: Intravenous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed.
Study: NCT06219018
Drug: Medical grade honey formulation (MGH) (L-Mesitran®)
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.
Study: NCT06393400
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Gemzar
Study: NCT06393400
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Abraxane
Study: NCT04978428
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
Study: NCT06151080
Drug: Lenalidomide combined with G-CHOP (LO CHOP)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
Study: NCT06434610
Drug: B013
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
Study: NCT06434610
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.
Study: NCT04525755
Drug: Varenicline 0.5 MG
Normalized name: varenicline 0.5 MG
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: varenicline comes in bottles of 56 - 0.5 mg pills
Study: NCT04525755
Drug: Nicotine Replacement Therapy (NRT)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
Study: NCT04408989
Drug: MB02-DM
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Study: NCT04246151
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin capsules
Study: NCT04246151
Drug: Vancomycin Placebo
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sugar pill manufactured to mimic the vancomycin 125 mg capsule
Study: NCT04781959
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
Study: NCT04781959
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
Study: NCT05103696
Drug: Remimazolam Besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min
Study: NCT05103696
Drug: etomidate combined with propofol
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
Study: NCT05675202
Drug: TQ-B3525
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-B3525 is a new PI3K α/δ Kinase inhibitor
Study: NCT05178511
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
Study: NCT06376942
Drug: Glycopyrronium
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrronium 50 mcg
Study: NCT06376942
Drug: Ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized iptratropium 500 mcg
Study: NCT05804747
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is observational, non-interventional study. No study drug will be administered during this study.
Study: NCT05945797
Drug: Dexamethasone 4mg
Normalized name: DEXAMETHASONE 4MG TAB
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.
Study: NCT06108232
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT06108232
Drug: CC-99282
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO